E. Beggiato

发表

M. Ballmaier, P. Noris, P. Knight, 2014, Human mutation.

Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod

L. Pinessi, P. Cavalla, P. Broganelli, 2014, Multiple sclerosis.

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

M. Boccadoro, A. Pileri, J. Even, 1999, Blood.

Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy

M. Boccadoro, A. Pileri, J. Even, 1999 .

Second cancers in MPN: Survival analysis from an international study

M. Griesshammer, T. Barbui, A. Patriarca, 2019, American journal of hematology.

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.

A. Pileri, P. Borrione, M. Massaia, 1996, Leukemia & lymphoma.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

M. Griesshammer, T. Barbui, A. Patriarca, 2019, Leukemia.

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis

A. Cuneo, M. Krampera, D. Cilloni, 2021, Cancer.

Novel CALR somatic mutations in essential thrombocythaemia

S. Ferrero, S. Osella-Abate, L. Riera, 2016, British journal of haematology.

DISTRIBUTION OF T‐CELL SIGNALLING MOLECULES IN HUMAN MYELOMA

M. Boccadoro, A. Pileri, S. Mariani, 1997, British journal of haematology.

Correlation between disease activity and T‐cell CD3 chain expression in a B‐cell lymphoma

A. Pileri, M. Massaia, A. Bianchi, 1994 .

Can pegylated interferon improve the outcome of polycythemia vera patients?

M. Boccadoro, D. Ferrero, L. Riera, 2017, Journal of Hematology & Oncology.

The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

M. Boccadoro, V. Martinelli, D. Cilloni, 2018, British journal of haematology.

The use of erythropoiesis stimulating agents (ESAs) is safe and effective in the management of anemia in myelofibrosis patients treated with Ruxolitinib Running title: Erythropoiesis-stimulating agents (ESAs) are effective in improving anemia in MF patients treated with Ruxolitinib without significa

M. Boccadoro, V. Martinelli, D. Cilloni, 2022 .

Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients.

M. Boccadoro, A. Pileri, P. Borrione, 1995, Blood.

SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey

C. Girmenia, S. Sica, E. Metafuni, 2022, American journal of hematology.

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study.

M. Griesshammer, T. Barbui, A. Patriarca, 2019, Blood.

A novel point mutation in severe haemophilia A: a further proof of genotype‐phenotype correlation

M. Bicocchi, A. Borchiellini, M. Acquila, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms

L. Riera, G. Benevolo, A. Pich, 2021, Expert review of hematology.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

M. Cazzola, M. Griesshammer, T. Barbui, 2018, Blood Cancer Journal.

Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia

G. Cappellano, A. Chiocchetti, U. Dianzani, 2017, British journal of haematology.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

M. Boccadoro, A. Nagler, D. B. Yehuda, 2012, Blood.

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study

A. Busca, D. Ferrero, R. Freilone, 2022, Annals of Hematology.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

C. Patrono, A. Vannucchi, A. Tosetto, 2018, Blood Cancer Journal.

Increased expression of non‐functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients

M. Boccadoro, A. Pileri, S. Mariani, 2000, British journal of haematology.

JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia

L. Riera, G. Benevolo, A. Pich, 2018, Acta Haematologica.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

M. Cazzola, M. Griesshammer, T. Barbui, 2018, Blood Cancer Journal.

Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

M. Boccadoro, S. Ferrero, A. Larocca, 2020, Annals of Hematology.

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia

C. Patrono, A. Vannucchi, A. Tosetto, 2021, Clinical pharmacology and therapeutics.

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

C. Patrono, A. Vannucchi, A. Tosetto, 2020, Blood.

Laboratory Aspirin Resistance Reversibility in Diabetic Patients: a Pilot Study Using Different Pharmaceutical Formulations

F. Gaita, R. Grimaldi, M. Tagliabue, 2014, Cardiovascular Drugs and Therapy.

Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges

B. Bruno, D. Ferrero, R. Freilone, 2023, Current Treatment Options in Oncology.

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

A. Cuneo, M. Krampera, D. Cilloni, 2023, Cancer.

COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey

F. Lanza, R. Notaro, C. Carbone, 2021, British journal of haematology.

Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

M. Griesshammer, T. Barbui, A. Patriarca, 2019, Leukemia.

JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia

P. F. di Celle, L. Riera, P. Campisi, 2012, Journal of Clinical Pathology.

C. Patrono, A. Vannucchi, A. Tosetto, 2018, Blood Cancer Journal.

Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera

R. Melchio, D. Rapezzi, E. Beggiato, 2023, Vascular health and risk management.

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

A. Vannucchi, A. Tosetto, N. Vianelli, 2024, American journal of hematology.